Unknown

Dataset Information

0

Structure and Characterization of a Covalent Inhibitor of Src Kinase.


ABSTRACT: Unregulated Src activity promotes malignant processes in cancer, but no Src-directed targeted therapies are used clinically, possibly because early Src inhibitors produce off-target effects leading to toxicity. Improved selective Src inhibitors may enable Src-directed therapies. Previously, we reported an irreversible Src inhibitor, DGY-06-116, based on the hybridization of dasatinib and a promiscuous covalent kinase probe SM1-71. Here, we report biochemical and biophysical characterization of this compound. An x-ray co-crystal structure of DGY-06-116: Src shows a covalent interaction with the kinase p-loop and occupancy of the back hydrophobic kinase pocket, explaining its high potency, and selectivity. However, a reversible analog also shows similar potency. Kinetic analysis shows a slow inactivation rate compared to other clinically approved covalent kinase inhibitors, consistent with a need for p-loop movement prior to covalent bond formation. Overall, these results suggest that a strong reversible interaction is required to allow sufficient time for the covalent reaction to occur. Further optimization of the covalent linker may improve the kinetics of covalent bond formation.

SUBMITTER: Gurbani D 

PROVIDER: S-EPMC7248381 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure and Characterization of a Covalent Inhibitor of Src Kinase.

Gurbani Deepak D   Du Guangyan G   Henning Nathaniel J NJ   Rao Suman S   Bera Asim K AK   Zhang Tinghu T   Gray Nathanael S NS   Westover Kenneth D KD  

Frontiers in molecular biosciences 20200519


Unregulated Src activity promotes malignant processes in cancer, but no Src-directed targeted therapies are used clinically, possibly because early Src inhibitors produce off-target effects leading to toxicity. Improved selective Src inhibitors may enable Src-directed therapies. Previously, we reported an irreversible Src inhibitor, DGY-06-116, based on the hybridization of dasatinib and a promiscuous covalent kinase probe SM1-71. Here, we report biochemical and biophysical characterization of t  ...[more]

Similar Datasets

| S-EPMC7493195 | biostudies-literature
| S-EPMC9710212 | biostudies-literature
| S-EPMC6481345 | biostudies-literature
| S-EPMC3423592 | biostudies-literature
| S-EPMC5648430 | biostudies-literature
| S-EPMC6004567 | biostudies-literature
| S-EPMC3763859 | biostudies-literature
| S-EPMC8253829 | biostudies-literature
| S-EPMC10330000 | biostudies-literature
| S-EPMC10108393 | biostudies-literature